RaySearch Laboratories Showcases Strong Q2 Performance

RaySearch Laboratories Reports Strong Second Quarter Results

RaySearch Laboratories has recently reported its results for the second quarter of 2025, showcasing some impressive numbers that highlight the company's resilience and growth amidst challenges in the healthcare sector.

Second Quarter Financial Highlights

During the second quarter (April to June), RaySearch experienced a solid order intake of SEK 241.2 million, although this was a decline from SEK 290.3 million in the previous year. The net sales during this period amounted to SEK 304.9 million, down from SEK 318.9 million from the previous year. Operating profit saw a decrease to SEK 36.4 million, compared to SEK 79.3 million last year, while profit after tax dropped to SEK 30.8 million from SEK 61.4 million. This translated to earnings per share (EPS) before and after dilution of SEK 0.90, down from SEK 1.79. Meanwhile, cash flow from operating activities was SEK 70.6 million, significantly lower than SEK 154.6 million from the same period last year. Lastly, the order backlog at the end of the period stood at SEK 1,665.3 million, compared to SEK 1,790.5 million previously.

Half-Year Performance Overview

For the first half of the year (January to June), the company reported an order intake of SEK 650.8 million, which was a significant improvement over the previous year’s SEK 528.8 million. Net sales increased as well, reaching SEK 636.6 million compared to SEK 576.1 million the previous year. Operating profit totaled SEK 111.2 million, a slight decrease from SEK 125.1 million, while profit after tax was SEK 87.6 million, down from SEK 98.1 million. Earnings per share for the half-year stood at SEK 2.55, compared to SEK 2.86 last year, with cash flow from operations reported at SEK 217.4 million versus SEK 321.9 million.

Significant Achievements in Q2

During the second quarter, several noteworthy events took place. One of the highlights was the decision made by Odense University Hospital to place an order aimed at enhancing automation through the RayStation treatment planning system. Additionally, in May, the company launched RayStation v2025, which features rapid automated treatment planning enhanced by machine learning and the ECHO algorithm, along with supplemental support for patients requiring upright treatment planning.

A milestone moment occurred at the Royal Marsden Hospital, where for the first time globally, a patient was treated using RayStation's adaptive re-planning module during online adaptive radiotherapy. Furthermore, RaySearch obtained recognition at Helsinki University Hospital for being involved in Europe’s pioneering accelerator-based BNCT treatments. June saw the introduction of RayCare v2025, which boasts powerful new functionalities that enhance workflow, optimize data management, and boost interoperability throughout treatment processes.

Post-Reporting Developments

Following the end of the reporting period, RaySearch announced a strategic partnership with Radiology Oncology Systems, Inc. (ROS), focusing on integrating refurbished linear accelerators with innovative software solutions. Additionally, AKSM/Oncology has selected RayCare and RayStation for a new cancer center, reflecting the growing trust in RaySearch's groundbreaking technology.

CEO Webcast Announcement

RaySearch Laboratories will conduct a webcast featuring CEO Johan Löf and CFO Nina Grönberg, who will discuss the interim report and answer inquiries on their strategies moving forward. This webcast is an excellent opportunity for stakeholders to engage with the leadership team and gain insight into the future direction of the company.

About RaySearch Laboratories

RaySearch Laboratories AB (publ) is recognized as a leading medical technology company focused on developing state-of-the-art software solutions to enhance cancer treatment. Products include the innovative RayStation treatment planning system and RayCare oncology information system. Recently, the company expanded its offerings with RayIntelligence and RayCommand systems, which are designed to improve data analytics and streamline treatment processes respectively.

Since its establishment in 2000 as a spin-off from the Karolinska Institute, RaySearch has sold its software to over 1,100 clinics across 47 countries. The company's shares have been listed on Nasdaq Stockholm since 2003, marking its significant journey in the med-tech industry.

Frequently Asked Questions

What were RaySearch Laboratories' order intake figures for Q2 2025?

During Q2 2025, RaySearch reported an order intake of SEK 241.2 million.

How did RaySearch's net sales compare year-on-year for Q2?

Net sales were SEK 304.9 million in Q2 2025, down from SEK 318.9 million in the previous year.

What significant events occurred during the second quarter?

Key events included the launch of RayStation v2025 and RayCare v2025, as well as notable clinical milestones in patient treatment.

What is RaySearch’s focus in its software development?

RaySearch is dedicated to creating innovative solutions aimed at enhancing the efficacy and efficiency of cancer treatment.

What is the history of RaySearch Laboratories?

Founded in 2000, RaySearch Laboratories originated as a spin-off from the Karolinska Institute and has since grown to serve over 1,100 clinics worldwide.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.